Following the release of favorable Phase I/IIa results with Ionis Pharmaceuticals Inc.'s antisense compound, IONIS-HTTRx, in patients with Huntington's disease on Dec. 11, analysts have been positive about Roche's decision to exercise its option on the drug, with the big pharma now being responsible for all future development and commercial activities.
"The Roche decision is a win for Ionis," said analysts at Leerink, who estimated the market for Huntington's disease